Teva Pharma (TEVA) and MODAG Collaborate on Neurodegenerative Disease Drug Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- S&P 500, Nasdaq futures slip as investors eye SK Hynix listing, Middle East risks
- Oil heads for weekly gain as Middle East supply risks persist
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
October 26, 2021 4:45 PM EDTSmall molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders
TEL AVIV & WENDELSHEIM, Germany--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound,... More
